Introduction
This is the third fungal diagnosis and management clinical guideline published in cooperation with various European scientific societies [1e9] . This part of the guideline regarding invasive and chronic aspergillosis is a condensation of all the recommendations made by the guideline subcommittees and is presented in tables for easier and faster reading. More details on how the recommendations were arrived at are planned in supplementary publications. This Aspergillus guideline will follow the style of other guidelines by including diagnostic and therapeutic guidance. Other scientific groups have published guidelines on this topic previously and all follow the common goal to provide clinicians with best guidance in their everyday working environment. Our goal was to provide a comprehensive European guideline focusing on the life-threatening diseases caused by Aspergillus spp.
Methods
Author panel recruitment and organization was similar to what was done previously [10] . In brief, experts in the field were nominated by the three societies: European Society for Clinical Microbiology and Infectious Diseases (ESCMID), the European Confederation of Medical Mycology (ECMM) and the European Respiratory Society (ERS). The total of 53 authors were grouped into their special fields of expertise. Subgroup coordinators were responsible for the first draft of recommendations. There were two face-to-face meetings followed by numerous electronic exchanges. Some of the first recommendations were presented at ECCMID 2014. This summary was reviewed and approved by all authors and sent to the ESCMID guideline director for public review. Then the final version was submitted to Clinical Microbiology and Infection for additional peer review and subsequent publication. Only the rationale of the chronic pulmonary aspergillosis (CPA) guideline was published ahead of time [11] .
Questions were predefined and modified where appropriate and the strength of recommendation and quality of evidence was slightly modified (Table 1 ) [12] . Diagnostic tests are regarded as interventions.
Summary of recommendations

Diagnostic procedures
Early diagnosis of invasive aspergillosis (IA) is a challenge and should be based on the integration of clinical, radiological and microbiological data.
Thoracic imaging
In patients at risk for IA with fever of unknown origin or clinical symptoms of lower respiratory tract infection who remain febrile despite broad-spectrum antibacterial treatment, thin-section chest computed tomography (multidetector (MDCT), multislice (MSCT), spiral CT, high resolution CT) at optimized dose (according to the ALARA ('As Low As Reasonably Achievable') principle) is the imaging modality of choice (AII) [13e23] . Pulmonary CT angiography may be of interest in the early diagnosis of IA by depicting directly vessel occlusion at the level of a suspicious fungal lesion with a potential high negative predictive value regarding imaging evaluation [24e26], and is required in case of haemoptysis (AII). In selected patients where CT is not wanted or not feasible, magnetic resonance imaging (MRI) of the lungs may represent an alternative imaging to thin-section MSCT [27e32], positron emission tomography-CT being of modest interest in the diagnostics of IA [33, 34] .
No CT scanning technique is 100% sensitive or specific for pulmonary IA [35e37] . Classical CT findings of angioinvasive aspergillosis include macronodule(s) >1 cm, which may be surrounded by a halo of ground-glass attenuation (halo sign, early phase, inconstant) [36,38e40] , pleural based wedge-shaped areas of consolidation [41] , alveolar consolidations [36, 42, 43] , masses (especially in solid organ transplant (SOT) recipients) [15, 38] , internal low attenuation [44] , reverse halo sign [45] , cavity or air-crescent sign (delayed finding), ground glass opacities and pleural effusion [17, 35, 46] . Bronchoinvasive forms may appear as tracheal or bronchial wall thickening, centrilobular nodules with tree in bud appearance [14] in a patchy distribution, predominant peribronchial areas of consolidation [47] or bronchopneumonia [46] (Table 2) .
Bronchoalveolar lavage and biopsies
Other diagnostic procedures include early bronchoalveolar lavage (BAL) (AII) [48e54] , guided by CT findings [55, 56] , and less frequently CT-guided transthoracic biopsies, video-assisted thoracoscopic surgery, open lung biopsies, transbronchial biopsies or convex endobronchial ultrasound transbronchial needle aspiration, the latter technique appearing to be a promising procedure in this setting [28,57e72] . Contraindications to these techniques need to be considered.
Imaging of other sites
Moreover, according to clinical symptoms, paranasal CT, CT or MRI of the central nervous system (CNS) as well as abdominal CT may also be required. In particular, findings of sinusitis with bone erosion may be observed, intracranial and/or intraorbital extension of the disease being best evaluated by MRI [73e75] . In the brain, due to direct spread from paranasal sinuses or haematogenous dissemination, meningeal enhancement or empyema, cerebral abscess, mycotic aneurysms as well as haemorrhagic lesions and rarely stroke may be seen [76e79] .
Microscopy and culture
Both microscopy and culture should be attempted on appropriate specimens from patients at risk for IA (AII) with a priority for culture in most cases where insufficient material is available. Demonstrating tissue invasion by hyphae through microscopic examination of biopsy or autopsy material provides a diagnosis of proven invasive fungal infection. However, the sensitivity of microscopy for IA is 50% at best [80] . Specimens may be examined as a wet mount preparation with or without the addition of 10% potassium hydroxide. Fluorescent dyes such as Calcofluor White™ or Blancophor™ have the advantages of increased sensitivity, rapid turnaround time and broad applicability but are not specific for Aspergillus (AII). Gomori's methenamine silver stain (GMS) and periodic acid-Schiff (PAS) can be applied to histological sections and smears and should be conducted in all cases in which IA is considered a possibility (Table 3) . Respiratory secretions from patients with suspected aspergillosis must be processed rapidly for culture to prevent overgrowth by bacteria and yeasts. To achieve optimal recovery of Aspergillus from BAL fluid, centrifugation of the sample is advised with investigation of the sediment (AIII). It is recommended that cultures of high volume untreated sputum and BAL should be performed as opposed to culturing small volumes of digested, liquefied samples [81] (Table 4) . Specific media to support fungal growth are recommended. Species identification to the complex level should be carried out for clinically relevant isolates from patients who need antifungal treatment, and for epidemiological purposes (AIII) ( Table 5 ).
Non-culture based assays
Galactomannan (GM) detection in fluids (especially BAL) is more sensitive than culture for diagnosis of IA. GM is reported as optical density index (ODI). In serum samples an ODI cut-off of 0.5 results in high sensitivity in haematological patients in the absence of mouldactive prophylaxis (AI) ( Table 6 ). Serial screening for serum GM in prolonged neutropenia and in allogeneic stem cell transplantation recipients during the early engraftment phase has a high sensitivity and negative predictive value for IA (AII) [82] . Serial screening is not recommended in patients on mould-active prophylaxis [83] . Abbreviations: BAL, bronchoalveolar lavage; PCR, polymerase chain reaction; QoE, Quality of evidence; SoR, Strength of recommendation. [384, 385] To study outbreaks Microsatellite and CSP analysis C II To study outbreaks (which in general may comprise more than one genotype)
[386e388] B II To study colonization patterns [389] Abbreviations: BHI, braineheart infusion; CSF, cerebrospinal fluid; CSP, cell surface protein; ITS, internal transcribed spacer; MALDI-TOF MS, matrix-assisted laser desorption/ ionization time-of-flight mass spectometry identification; MEA, malt extract agar; PDA, potato dextrose agar; QoE, Quality of evidence; SDA, Sabouraud dextrose agar; SoR, Strength of recommendation. Sensitivity of serum GM testing is significantly lower in nonneutropenic versus neutropenic patients [84] . Decrease of the ODI during the first 2 weeks of antifungal therapy is a reliable predictor of a satisfactory response in cancer patients [85] . GM detection in BAL specimens has an excellent performance with evidence that ODI of 0.5e1.0 has decreased predictive values compared with results of >1.0 [86] (AII) ( Table 7 ). The test also has diagnostic value in patients undergoing lung transplantation or who are in intensive care [87e89]; a sensitivity of 100% and a specificity of 90.4% was defined at cut-off of 1.5 [87] .
A constituent of the cell wall of many species and genera of fungi, (1-3)-b-D-glucan (BDG), is released into body fluids in association with fungal infection. A limited role is given for the exclusive testing of the BDG in diagnosing IA (BII) (Table 8) ; however, the combination with GM or PCR improves specific detection [90] .
The Aspergillus lateral flow device assay can be performed on serum and on BAL samples, but at the time of writing this assay is not commercially available [91] (Table 9) .
Aspergillus PCR has been applied mostly to blood and BAL fluid. For both sample types, a combination with other biomarkers increases the likelihood of IA [92, 93] . The performance of serum PCR is not significantly different from that of whole blood [94e97] . Prospective screening of high-risk haematological patients by a combination of GM and PCR improves the diagnostic accuracy and is associated with an earlier diagnosis [98, 99] (Tables 10 and 11 ).
On hyphal positive biopsy samples molecular detection of fungi is strongly recommended (AII). If no hyphae are visible the diagnostic yield of molecular methods is lower (Table 12) . Recommendations for storage of original samples and isolates are given in Table 13 . Antibody detection tests are not supported for the diagnosis of IA (CII) ( Table 14) .
Antifungal susceptibility testing
Resistance to antifungal agents is an increasing problem in Aspergillus diseases [100e102] . Aspergillus species can be intrinsically resistant to polyenes and azoles [103] , or may acquire resistance following exposure to azole compounds [104] . Acquired resistance to azoles is mainly found in Aspergillus fumigatus and is reported globally [100,101,105e108] . Resistance may also develop through exposure to azole fungicides in the environment [109e112]. As resistant spores are present in ambient air, patients may present with azole-resistant Aspergillus disease without previous azole therapy [113, 114] . Individual Aspergillus colonies from a single specimen may harbour different resistance profiles [117] , hence multiple colony testing (up to five colonies) is recommended to increase sensitivity for azole-resistance detection (BIII).
In clinical laboratories, species identification to complex level is recommended for all clinically significant isolates (BIII). Some species are intrinsically resistant to either azoles or amphotericin B (Tables 5, 15e17 ). To diagnose IA PCR on serum samples 97% of protocols detected threshold of 10 genomes/mL serum volume >0.5 mL, elution volume <100 mL, sensitivity: 86%; specificity: 94% [461] To diagnose IA PCR on whole blood samples First blood PCR assay to be compatible with EAPCRI recommendations, fever driven: Sensitivity: 92%, specificity: 95%, negative PCR result to be used to rule out IA [462] Haematopoietic stem cell transplantation Antifungal susceptibility testing of Aspergillus isolates should be performed in patients with invasive disease with the exception of azole-naive patients in regions with no resistance found in contemporary surveillance programmes and regularly for epidemiological purposes including !100 isolates. This is particularly important in patients who are unresponsive to antifungal treatment, or in patients who are clinically suspected of having an azoleresistant pathogen (AIII) ( Table 15 ). If MIC testing is not available, routine agar screening can be used to detect azole resistance (Table 16 ) [118] . However, such isolates should be referred to a mycology reference laboratory for MIC testing. Clinical breakpoints for interpretation of azole and amphotericin B MICs against Aspergillus are currently available for the European Committee on Antimicrobial Susceptibility Testing (EUCAST) microdilution method but remain undetermined for Clinical & Laboratory Standards Institute (CLSI) methodology. Accordingly, EUCAST (AII) or CLSI broth microdilution methods (BII) can be used for determination of routine MICs for clinical guidance and for epidemiological resistance surveillance (AII). Both itraconazole and voriconazole (AII) should be tested to ensure detection of the voriconazoleresistance mutation TR 46 /Y121F/T289A [118] . Posaconazole resistance without itraconazole resistance has not been reported (Table 17) . EUCAST (BIII) or CLSI broth microdilution methods (CIII) can be used to determine amphotericin B MICs but although a correlation between MIC and clinical outcome exists for Aspergillus terreus and Aspergillus flavus it remains to be documented for A. fumigatus due to the scarcity of resistant isolates (Table 17) .
Voriconazole and isavuconazole are recommended for the treatment of IA due to species showing high amphotericin B MICs (Table 18 ). Liposomal amphotericin B or amphotericin B lipid complex (ABLC) are recommended for species with intrinsic high azole MICs (Tables 19 and 20 ). In aspergillosis due to A. fumigatus specifically, voriconazole or isavuconazole are recommended if the isolate is voriconazole-susceptible (EUCAST MIC 1 mg/L) (AI). If resistant (voriconazole MIC >2 mg/L), liposomal amphotericin B therapy is recommended (AII u ). It is unknown if patients infected with A. fumigatus with voriconazole MIC 2 mg/L (intermediate), respond less well to voriconazole monotherapy. These patients may have an increased probability of failing voriconazole monotherapy, and combination therapy with an echinocandin or liposomal amphotericin B monotherapy should be considered for invasive disease (AIII) ( Table 20) . In azole-resistant CPA, liposomal amphotericin B or micafungin can be considered (BII) if surgical intervention is precluded [11] . In settings with environmental azole resistance, no change to the primary regimen for IA is recommended when resistance rates are <10% (AIII). If azole resistance rates are >10%, first-line therapy with voriconazole plus echinocandin (BIII) or liposomal amphotericin B (BIII) is recommended.
Therapeutic drug monitoring
Patients with IA often have multiple conditions associated with their underlying disease and its treatment that affects the absorption, distribution, metabolism and clearance of antifungal medications [119] . As a result, standardized dosing recommendations for antifungals used in the prevention or treatment of IA may not achieve effective or safe drug exposures in all patients. Moreover, a subset of patients with severe infections or difficult to treat sites (e.g. CNS) or infections caused by Aspergillus spp. with elevated MICs may require higher drug exposures. Therapeutic drug monitoring (TDM) is often the most direct laboratory approach for identifying patients at jeopardy for treatment failure or toxicity because of inadequate or excessive drug exposures, and can be used to fine-tune antifungal dosing to improve the probability of optimal outcomes (Table 21) .
Itraconazole
For itraconazole, a serum trough of 0.5e4 mg/L (measured by HPLC) is recommended for prophylaxis (AII (efficacy), BII (safety)) and a trough of 1e4 mg/L is recommended during the treatment of IA (AII (efficacy), BII (safety)) [120e125] . Itraconazole has an active metabolite, OH-itraconazole that is present in concentrations similar to those of the parent itraconazole compound (1:1) when patients are at pharmacokinetic steady state. OH-itraconazole concentrations may be reported separately when samples are analysed by HPLC or LC/MS/MS, but will be included in the overall report of 'itraconazole' concentrations if samples are analysed by bioassay [126, 127] . Therefore, the target range for itraconazole is higher when reported by bioassay (i.e. 3e17 mg/L) but may vary by laboratory depending on the reference standards used. Samples should be acquired within 5e7 days of starting therapy. Repeat TDM is recommended the following week to confirm that the patient remains in the therapeutic range, and repeated thereafter as clinically indicated if there are changes in the patient's clinical condition, concomitant medications known to interact, or suspected toxicity (Table 22) . Steady-state concentrations can often be predicted from earlier (non-steady) state samples through pharmacokinetic models or computerized dosage-assistance. In centres where these tools are available, sampling before day 5e7 may be preferable.
Voriconazole
A plasma trough concentration of 1e5.5 mg/L is considered adequate for most patients receiving voriconazole prophylaxis or treatment (AII, safety and efficacy) [128e133]. However, a trough of 2e6 mg/L (AII, safety and efficacy) is recommended in patients treated for severe infections (multifocal or disseminated disease, CNS infections, infection with pathogen with elevated MICs, e.g. an MIC of 2 mg/L) [130, 131] . TDM is strongly recommended in children due to the much higher rates of drug elimination and potential for underdosing, especially with the lower voriconazole doses recommended in the past (AII) [134, 135] . Plasma levels should be monitored between 2-5 days after initiation of therapy, and repeated the following week to confirm that the patient remains in the therapeutic range. Repeated monitoring is indicated until steady-state level in the therapeutic range is confirmed, if there are changes in the patient's clinical condition, concomitant medications, or suspected toxicity (Table 23) .
Posaconazole
For patients receiving posaconazole suspension, a plasma trough of >0.7 mg/L is recommended during prophylaxis (BII, efficacy) [136, 137] ; and a trough of >1 mg/L is recommended if the patient is receiving treatment for suspected or documented IA (AII, efficacy) [138] . Currently, no studies have defined an upper plasma target that is associated with toxicity, although pharmacokinetic studies supporting the registration of the new posaconazole tablet and intravenous formulations with the EMA used a provisional cutoff of 3.75 mg/L [139e141]. Posaconazole plasma trough levels should be monitored on day 5 of therapy or soon thereafter, and repeated as clinically indicated.
For most patients prescribed posaconazole, we recommend using the newer tablet formulation (or intravenous formulation, if tablet formulation is contraindicated) rather than the suspension (AII), as tablets are more likely to consistently achieve target plasma levels and are less affected by gastrointestinally dependent drug interactions [139] . Currently, there is limited evidence to suggest that all patients receiving posaconazole tablets or intravenous formulation for prophylaxis require routine TDM; however, our opinion is that when treating suspected or documented Aspergillus infections, TDM could still be useful if the pathogen has elevated MICs, is unresponsive to treatment, or in the event of unexplained toxicity (BIII). Until further data are available, we recommend using TDM monitoring strategies and plasma trough Exposure-response relationships are described for other toxicities (e.g. hepatotoxicity), the utility of therapeutic drug monitoring to prevent their occurrence is less well established targets as detailed above and suggested for the suspension formulation (Table 24) .
Isavuconazole
Although doseeresponse and plasma concentrationeresponse relationships for isavuconazole have been reported in animal models, limited data are currently available to define a target therapeutic range or support the need for routine TDM for this agent [142] . Our opinion is that TDM could still be useful in the clinical assessment or monitoring of patients receiving isavuconazole therapy (CIII) if patients are unresponsive to treatment, have unexpected toxicity, pharmacokinetic drugedrug interactions, or if isavuconazole is being used to treat pathogens with elevated MICs or sanctuary sites such as the CNS. In the absence of well-defined therapeutic targets, documentation of a plasma trough in the range of 2e3 mg/L (mean concentration range from phase II/III clinical studies) after day 5 (including loading doses) suggests adequate drug exposure (Table 25 ).
Flucytosine
In rare circumstances, flucytosine may be used in combination with other antifungals for the treatment of triazole-resistant Aspergillus spp. In this scenario, weekly measurements of peak serum concentrations 2 h following an oral dose (AII) are needed to confirm that peak concentrations are 50e100 mg/L to reduce the risk of toxicity. Trough concentrations required for efficacy are unknown but a level of 25e50 mg/L is recommended based upon experience from cryptococcosis [143, 144] .
Hospital environment
Standards for the hospital environment in immunosuppressed adults and children require special attention. Patients need to be segregated from construction or renovation (AII h ), potted plants (BII), and flowers in wards and in patients' rooms (CIII) [145e150] . Published data support the recommendation to accommodate patients in special hospital rooms with positive air pressure and HEPA filters (BII) or laminar airflow (BII h ). However, data were with historical controls, underpowered, or described by multivariate analysis describing high-risk situations for IA [151e154] . Protective masks for patients are proven not to be effective outside the protected area (CII) [155] . Filters for water supply, especially in showers, are recommended (BII) [156e160] . No data are available to support regular environmental air sampling to prevent infections. However, indoor sampling is advisable to monitor filter efficacy (BIII) [161, 162] . 
Treatment strategies
Two strategies are accepted for managing patients with haematological malignancy at risk for IA: (i) the patient receives primary prophylaxis or (ii) the patient receives no prophylaxis but is monitored at least twice weekly using biomarkers. The decision between the two strategies depends on local epidemiology, access to rapid diagnostics and patient characteristics. Breakthrough fungal diseases may appear through either symptoms or a diseaseidentifying biomarker or imaging result. Fig. 1 depicts a consensus algorithm for patient management.
Primary prophylaxis
At least three studies describe a number of patients who succumbed with IA missed before death [163e165]. Although diagnostic procedures have improved since then, they are not satisfactory. For this reason, patients known to be at high risk for IA may receive primary prophylaxis, especially patients with profound and prolonged neutropenia or with active graft-versus-host disease (GvHD) ( Table 26) .
Aspergillosis in haematological malignancy and haematopoietic stem cell transplantation
In patients treated for haematological diseases, prolonged severe neutropenia is the most important risk factor for the development of IA. T-cell-depleted grafts, glucocorticosteroids and other immune suppressive drugs have been identified as further risk factors for IA in the later course after haematopoietic stem cell transplantation (HSCT), even in non-neutropenic patients [166] . In fact, up to two-thirds of patients with IA diagnosed after allogeneic HSCT are not neutropenic [167] , and the median time of diagnosis of IA after allogeneic HSCT is 82 days (range, 3e6542 days) [168] .
Treatment
Providing a definite diagnosis of IA is a continuously challenging endeavour for clinicians. The EORTC/MSG definitions are only designed for clinical studies. For clinical decision-making, these definitions could have a deleterious outcome as confirmation of a proven or probable diagnosis would delay the start of therapy [169] . Any patient at risk considered by the responsible clinician as having IA should receive antifungal therapy (AIII) (Tables 27 and 28 ). Physicians should consider switching from intravenous to oral therapy in stable and pharmacokinetically reliable patients. Treatment duration depends on clinical response and on immune reconstitution or recovery from GvHD. Good partial or complete remission requires no persistent clinical, including imaging (scarring allowed), or microbiological evidence of disease. The range of the duration of treatment (3 to >50 weeks) is huge and the evidence base to support any particular Additional adjunctive therapy such as the administration of granulocyte colony-stimulating factor (G-CSF) or G-CSF-primed granulocyte infusions (data mainly from paediatric populations) received only a weak supportive recommendation (CIII). In refractory cases, G-CSF (or interferon-g) has immunomodulatory effects [174e179] . No controlled trials have been performed and only anecdotal data with small numbers of patients exist. Persistent neutropenia is related with treatment failure, recovery from neutropenia enhances the efficacy of antifungal agents. A recent Cochrane review investigating the efficacy of granulocyte transfusions indicated no mortality difference for any kind of infection in patients with neutropenia [180] .
Fever-driven ('empiric'), and diagnosis-driven ('pre-emptive') therapy
As an alternative to prophylaxis, patients could receive the classical empirical administration of antifungal agents during fever refractory to broad-spectrum antibacterial agents. Empiric treatment is defined as a fever-driven treatment approach. Patients who would qualify for this approach are patients receiving induction or remission chemotherapy for acute leukaemia or myelodysplastic syndrome or conditioning chemotherapy for HSCT. Empiric antifungal treatment is expected to reduce morbidity [181e186] and mortality [187, 188] (Table 29 ). The duration of empiric antifungal treatment is set by the following rules applied in randomized clinical trials. If the patient is afebrile and has no active infection or infiltrates, then antifungal therapy can be discontinued after recovery of leucocyte counts [188e190]. Today, antifungal stewardship may warrant clinical trials on empiric treatment duration, but no such trial has been conducted so far.
Pre-emptive treatment is a diagnosis-driven strategy. In most cases, it is defined by positive GM testing. However, chest CT with pulmonary infiltrates could apply as well. The use of BDG and PCR testing as alternative biomarkers for GM have considerable merit [191, 192] , though BDG is not specific for Aspergillus disease. In haematological patients, false-positive BDG often results from contaminated infusions [193e196] . Very few authors wait for Aspergillus-associated suggestive radiological signs including nodule, halo sign, wedge-shaped area of consolidation, ordlate in the course of invasive aspergillosisdthe air crescent sign, before starting antifungal treatment. Treatment choices are as recommended in targeted treatment.
Adult patients without haematological malignancy
Epidemiology
Approximately 43%e80% of the cases of IA appear in patients without a haematological malignancy [52,197e200] , although these patients are rarely included in the seminal studies of antifungals [170, 171, 173] . The proportion of these patients is even increased when exposed to spore concentrations of >25 CFU/m 3 in hospital air [201e204] . The non-haematological populations at risk for IA include SOT recipients, patients treated with prolonged highdose glucocorticosteroids, or with other immunosuppressants, patients with advanced AIDS or neoplasia, chronic obstructive pulmonary disease (COPD), liver failure, liver cirrhosis or influenza, as well as critically ill patients requiring admission to intensive care [52,197e199,205e208] . These patients frequently do not fulfil the EORTC/MSG criteria for invasive aspergillosis [169] . Confirmation of diagnosis may be delayed, resulting in high mortality rates. At the same time drugedrug interactions and toxicity can occur more frequently compared with haematological patients [52] . Physicians need to be aware of the specific risk factors, clinical manifestations and management challenges to improve outcome. In SOT recipients the average incidence of IA ranges from 0.1% to 11.6% [209, 210] , Abbreviations: allo-HSCT, allogeneic haematopoietic stem cell transplantation; AmB, amphotericin B; bid, twice daily; GM, galactomannan; IA, invasive aspergillosis; IV, intravenous; qd, once daily; QoE, Quality of evidence; SoR, Strength of recommendation; TDM, therapeutic drug monitoring; tid, thrice daily. with the highest risk in small bowel (11.6%) and lung (8.6%) transplant recipients, followed by patients receiving liver (4.7%), heart (4.0%), pancreas (3.4%) and kidney (1.3%) grafts [209e211].
Half the cases will occur in the first 3 months after transplantation, in patients with post-surgical risk factors. Late aspergillosis is more common in elderly recipients, and patients with pronounced immunosuppression due to rejection or post-transplant neoplasia or chronically impaired graft function [210, 212] . With the exception of lung transplantation, in which universal prophylaxis is still common, antifungal prophylaxis will target SOT recipients with additional risk factors [211] . Risk factors for early IA in all SOT recipientsdincluding heart transplantsdcomprise renal failure requiring replacement therapy, re-intervention, cytomegalovirus disease, and high environmental exposure to mould spores [211,213e215] . In liver transplantation, a high model for end-stage liver disease (MELD) score, transplantation in fulminant hepatic failure, high intraoperative transfusion needs or re-transplantation are considered indications for post-surgical prophylaxis [216e224]. In lung transplant recipients, risk factors include previous respiratory tract colonization with Aspergillus, single lung transplant, CMV disease and acquired hypogammaglobulinaemia [225e227]. In kidney transplantation risk factors include COPD, delayed graft function, bloodstream infection and acute graft rejection [228] and a >1.25 mg/kg/day average dose of prednisone [229] . Finally, some polymorphisms in defence genes have also been suggested to increase risk in transplant recipients [230, 231] . The incidence of IA in HIV patients has decreased since the advent of new antiretroviral therapy (2.2 cases per 10 000/year), but mortality remains high (38%) [232] . IA typically appears in patients with low CD4 counts and associated conditions such as neutropenia, advanced cirrhosis, liver transplantation or glucocorticosteroid therapy [233e241] . As in other non-haematological populations, EORTC/MSG criteria only detect half of the IA cases diagnosed among HIV-infected patients [232] and in a recent series of autopsies of AIDS patients, only 12% of the patients with IA had been diagnosed ante mortem [242] (Table 30) .
Invasive aspergillosis may affect 0.3% of patients with liver cirrhosis [243] . Both acute liver failure and advanced cirrhosis, mainly alcoholic hepatitis treated with glucocorticosteroids, have been recognized as risk factors for IA [205,244e246] . A low level of clinical suspicion explains that 53% of the cases of IA in cirrhotic patients are only recognized post-mortem [247] and that liver disease is independently associated with IA-related mortality [199, 248] .
Invasive aspergillosis has also been described in apparently immunocompetent patients in a critical condition as a complication of acute respiratory distress syndrome, COPD, influenza, pneumonia, burns, severe bacterial infection, surgery and malnutrition. Incidence is 4 to 6/1000 intensive care unit admissions and the mortality is higher than 70% in most series [245,249e252] . Glucocorticosteroid treatment was the major host factor [253, 254] and as in cirrhotic or HIV-positive patients delayed diagnosis is common [255, 256] . Individuals with COPD requiring glucocorticosteroids represent a group with especially high mortality [249, 257, 258] . Risk factors include admission to an intensive care unit, chronic heart failure and antibiotic treatment and, above all, the cumulative dose of glucocorticosteroids [257] .
Pulmonary and CNS aspergillosis predominates in these populations, but disseminated disease, fulminant and atypical forms may occur [203,214,225,251,259e267] . The sensitivity of most diagnostic methods is lower in non-haematological patients. Isolation of Aspergillus from respiratory cultures has a much lower positive predictive value so over-diagnosis has to be prevented [197,268e272] . Regarding imaging findings, angioinvasive presentation included in the EORTC/MSG criteria is uncommon in this setting [273] . Airway invasive radiological presentation was present in 37% of heart transplant recipients and was associated with delayed diagnosis and poorer prognosis [214, 274] . In COPD and HIV-positive patients, the most common radiological presentation was an alveolar infiltrate [273, 275, 276] . Experience with biomarkers and PCR is still scarce in these populations, but the combination of at least two different methods appears to be the best diagnostic approach [277e285] (Table 31) . 
Treatment
Despite no comparative studies of antifungal therapy in nonhaematological patients voriconazole remains the first option, as it has been related to reduced mortality [216,286e288] (Table 32) . Combination therapy is uncommon, although retrospective data were encouraging in SOT recipients [289] . The risks of drugedrug interactions and toxicity are very important in these populations and TDM is advisable [290e295]. In patients with liver insufficiency, liposomal amphotericin B is usually the first therapeutic option. Antifungal resistance is not a common problem despite prophylaxis [296, 297] , although some cases have been reported [298e300]. Finally, immune reconstitution syndrome may occur after therapy initiation [301] .
Most lung recipients receive antifungal prophylaxis. Targeted prophylaxis is preferred in the remaining SOT with risk factors [211,213,302e305] . However, significant variation in practice has been noted [221, 304, 306, 307] . To avoid drugedrug interactions and toxicity, echinocandins or inhaled amphotericin are preferentially used [308e311], although voriconazole has also demonstrated its efficacy and safety in this setting [217,220,312e314] . Duration of prophylaxis is adjusted to the presence of risk factors and, with the exception of lung recipients, is usually limited to 3e4 weeks [215] (Table 33) .
Special considerations in children
Presenting symptoms, distributions and patterns of diseases and vulnerability to IA are similar between children and adults. However, differences exist in epidemiology and underlying conditions, usefulness of newer diagnostic tools, pharmacology of antifungal agents and evidence from interventional phase III studies. Recommendations for paediatric patients are based on efficacy in phase II and III trials in adults, the availability of paediatric pharmacokinetic data, safety data and supportive efficacy data. In addition, regulatory approval is considered. Therapeutic drug monitoring is always recommended when mould-active azoles are used as prophylaxis or treatment.
Primary antifungal prophylaxis may be indicated in paediatric patients at 'high risk' for developing invasive fungal diseases, and specifically IA. An incidence rate of IFDs of !10% is usually considered as high risk. High-risk populations include children with de novo or recurrent leukaemia (e.g. acute myeloid leukaemia, acute lymphoblastic leukaemia depending on treatment protocol), bone marrow failure syndromes with profound and persistent neutropenia (e.g. myelodysplastic syndrome, very severe aplastic anaemia), allogeneic HSCT recipients, patients with chronic granulomatous disease and those undergoing lung transplantation. For patients with haematological disorders, the mould-active oral azoles are the first choice to prevent IA in children, although neither itraconazole nor posaconazole are licensed for use in patients <18 years of age. Due to the lack of paediatric data, recommendations for lung and high-risk liver transplant patients correspond to those given for adults [213, 315] . Secondary prophylaxis to prevent recurrence of IA when risk factors are persisting is recommended with an antifungal targeted at the previous Aspergillus species, which caused the first episode (see below and Table 34 ). Diagnostic procedures used in children are not different from those used in adults but their performance may differ. Suggestive abnormalities (e.g. halo sign, air crescent sign) on chest CT as described in adults are less common in children in which nonspecific masses or infiltrates predominate [316e318]. The GM test on blood and BAL samples have a similar sensitivity and specificity profile compared with adults [319e327]. The BDG test is not specific for Aspergillus and is not validated in children. Higher baseline levels are reported in healthy children and therefore the cut-off is unknown [328e332].
General management principles of IA are consistent with those in adults and include prompt initiation of antifungal therapy, control of predisposing conditions (e.g. reduction or discontinuation of glucocorticosteroids in immunosuppressed, administration of colony-stimulating factors in neutropenic patients), and surgical interventions on a case-by-case basis using a multidisciplinary approach. Voriconazole is recommended as the first-line agent to treat IA in all children except neonates (AIIt). Liposomal amphotericin B is first choice for neonates (AIII) and may replace voriconazole as first-line treatment in areas or institutions with a high prevalence of azole-resistant A. fumigatus. Upon diagnosis of invasive pulmonary aspergillosis, thorough evaluation for further sites of infection is required and should include the CNS. The optimal duration of therapy is determined by the resolution of all signs and symptoms and reversal of the underlying deficit in host defences. For salvage therapy and breakthrough infections, a switch to a different class of antifungals is recommended [123,132,138,170,171,177,333e341] (Table 35) .
If a fever-driven (empiric) strategy is used in at risk paediatric haematological patients, caspofungin or liposomal amphotericin B is recommended until resolution of fever and neutropenia [342e344]. Treatment recommendations for a diagnosis-driven (pre-emptive) strategy correspond to those made for targeted treatment [185, 186, 345, 346] .
Secondary prophylaxis
Secondary prophylaxis is a treatment strategy to prevent recurrence of IA during a subsequent risk period of immunosuppression. Patients with a history of IA previously successfully treated with antifungals entering a subsequent risk period of immunosuppression, e.g. allogeneic HCT (early phase), chemotherapy resulting in severe neutropenia (i.e. <500/mL and at least for 7 days), acute GvHD >I or extensive chronic GvHD, or T-cellsuppressing therapy, including steroids, are at risk. Agents for secondary prophylaxis are listed in Table 36 .
Treatment of refractory disease
Refractory IA is defined as progression of disease and should be differentiated from stable disease [349] . Patients with radiological evidence of progression and persisting elevated GM have a very high probability of treatment failure resulting in death. Assessment of response should use composite outcome parameters including clinical, radiological and mycological criteria. Radiological progression following or closely preceding neutrophil recovery should be carefully evaluated and is not necessarily indicative of failure. Keeping this in mind, assessing the response 2 weeks after treatment initiation generally allows prediction of the response, especially recognizing oncoming failure [350] . In case of GM-negative IA, early assessment of response may be difficult and could require a longer period of therapy. If failure is ascertained, look for poor vascular supply (i.e. sinusitis requiring surgical treatment), microbiological confirmation is recommended as identification of the fungus at the species level is pivotal. If a viable organism is recovered, susceptibility testing is recommended, especially regarding azole resistance. On the other hand, azole concentration should be monitored as well (see sections on resistance and therapeutic drug monitoring within this guideline) [38,85,349,351e357] . The choices of antifungal agents in refractory disease are listed in Table 37 .
Chronic pulmonary aspergillosis
Chronic pulmonary aspergillosis is an indolent destructive disease of the lungs usually complicating other pulmonary conditions occurring in non-or mildly immunocompromised patients [358, 359] . Its manifestations include chronic cavitary pulmonary aspergillosis (CCPA), which if left untreated may progress to chronic fibrosing pulmonary aspergillosis, Aspergillus nodule and single aspergilloma [11, 360] . Subacute invasive pulmonary aspergillosis (previously chronic necrotizing pulmonary aspergillosis) is also a cavitating destructive lung disease, usually found in moderately immunocompromised patients, which progresses more rapidly, typically over 1 to 3 months. The diagnosis of CPA requires a combination of characteristics: one or more cavities with or without a fungal ball present or nodules on thoracic imaging, either direct evidence of Aspergillus infection (culture or microscopy from biopsy) or an IgG antibody response to Aspergillus spp. and exclusion of alternative diagnoses (especially mycobacterial infection), all present for at least 3 months [11, 361] . Over 90% of patients have circulating Aspergillus antibody (precipitins) (AII) [362] . A positive culture of A. fumigatus respiratory tract secretion (BAL, bronchoscopy aspiration) is not diagnostic because many different pathologies are attributable to the fungus, and it may be an airwaycolonizing fungus or a plate contaminant in the laboratory.
If a fungal ball is seen, then only a positive test of Aspergillus IgG or precipitins confirms pathogenicity. Patients may have CPA and other infections concurrently (see below).
The distinctive hallmark of CCPA is new and/or expanding cavities with thick or thin walls in those with chronic lung disease. An intracavitary fungal ball may be present, often with pleural thickening and extensive parenchymal destruction and/or fibrosis. Patients may have CPA and other infections concurrently, Commercially not available everywhere [537, 732] Abbreviations: ABCD, amphotericin B colloidal dispersion; ABLC, amphotericin B lipid complex; bid, twice daily; IV, intravenous; L-AmB, Liposomal amphotericin B;; qd, once daily; qid, four times daily; QoE, Quality of evidence; SoR, Strength of recommendation; TDM, therapeutic drug monitoring. Typically, Aspergillus nodules appear rounded, some with low attenuation or cavitation within. Some are spiculated, a common feature of carcinoma [360] . If technically feasible, single aspergilloma should be surgically removed, preferably through a video-assisted thoracic surgery technique with due consideration for risks as recommended [363] . Long-term oral antifungal therapy is strongly recommended in patients with CCPA, partly to reduce general and respiratory symptoms [364, 365] , but also to minimize haemoptysis and prevent lung destruction and fibrosis (AII); itraconazole or voriconazole are effective for CCPA (AIII) [11] . Oral posaconazole is a potential alternative treatment (BII) [11] . Six months of therapy is the recommended minimum (AI) [11] . Relapse is common after discontinuation. Intravenous therapy for CPA is useful in patients who fail or are intolerant of triazoles or have triazole-resistant A. fumigatus. Prednisolone may be considered for underlying symptom control only if patients are adequately treated with antifungals. Mild and moderate haemoptysis usually responds to tranexamic acid; severe haemoptysis should be arrested with bronchial artery embolization (Table 38) .
Conclusions
This executive summary is a comprehensive guideline covering many aspects of Aspergillus diseases. It provides guidance for clinicians on prevention of disease, diagnostic procedures, resistance issues and treatment of IA as well as CPA. The guideline group intends to provide additional publications supporting the rationale of the recommendations given.
Finally, the guideline group provides comprehensive tables explaining various options for specific situations.
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